58 results
6-K
EX-99.1
IPA
ImmunoPrecise Antibodies Ltd
14 Mar 24
Current report (foreign)
8:21am
The strategy of IPA to provide a comprehensive range of services for antibody discovery and development is consistently yielding tangible outcomes. In the recent … our expansion strategy to meet customer needs.
BioStrand is generating fee-for-service revenue through its LENSai platform and is progressing
6-K
EX-99.1
IPA
ImmunoPrecise Antibodies Ltd
14 Mar 24
Current report (foreign)
8:00am
, and costs related to the execution of IPA's business plan and strategy; estimates and projections regarding the industry in which IPA operates … in areas such as oncology, inflammation, neurodegenerative diseases, autoimmunity, and atherosclerosis.
STRATEGY AND OUTLOOK
The management team
6-K
EX-99.1
IPA
ImmunoPrecise Antibodies Ltd
14 Dec 23
Current report (foreign)
8:38am
and strategy; estimates and projections regarding the industry in which IPA operates; the future success of research and development activities … , neurodegenerative diseases, autoimmunity, and atherosclerosis.
STRATEGY AND OUTLOOK
The management team at IPA places a strong emphasis on initiatives
6-K
EX-99.1
IPA
ImmunoPrecise Antibodies Ltd
14 Dec 23
Immunoprecise Antibodies LTD. 6-K
8:03am
of the launch of their LENSai portal and Software as a Service (SaaS) platforms. With our Talem assets, we remain committed to our strategy of driving … . Jennifer Bath, CEO of ImmunoPrecise Antibodies.
Business Highlights and Corporate Update
IPA's strategy to offer a fully integrated suite of antibody
6-K
EX-99.1
IPA
ImmunoPrecise Antibodies Ltd
27 Nov 23
Immunoprecise Antibodies LTD. 6-K
8:31am
appointed as Chairman of the Board, bringing a wealth of experience from the life sciences industry and financial strategy, particularly in Nasdaq market … operations. As CEO and Chairman of SmartHealth Dx since 2022, Levine has focused the company’s strategy, operational efficiency, and boosted corporate
6-K
EX-99.1
gw5lu4ue1gfsqucth
25 Oct 23
BioStrand Unveils Groundbreaking Retrieval Augmented Generation (RAG)-Based LLM Platform Integrated with Patented HYFT Technology
8:01am
6-K
EX-99.1
gl5 44rslud5lv
23 Oct 23
Immunoprecise Antibodies LTD. 6-K
8:01am
6-K
EX-99.1
0dz76e60 qvkirphv
20 Oct 23
Current report (foreign)
2:56pm
6-K
EX-99.1
927qo tr6fnm9
14 Sep 23
Current report (foreign)
8:02am
6-K
EX-99.1
10k7z9ok622r8rtt33
12 Sep 23
Material Change Report
6:20pm
6-K
EX-99.1
g1d57 j8uxa9fmk
5 Sep 23
IPA appoints Barry A. Springer, Dirk Witters and Chris Buyse to the Board of Directors
8:14am
40-F
EX-99.1
fp2gdo
10 Jul 23
Annual report (Canada)
4:32pm
40-F
EX-99.3
uwh7rgcv
10 Jul 23
Annual report (Canada)
4:32pm
6-K
EX-99.1
2z872ztvi rntcc
15 Dec 22
Current report (foreign)
8:00am
6-K
EX-99.1
5z6pas awso8x1d43d
14 Sep 22
Current report (foreign)
8:31am
6-K
EX-99.1
s3sgg2c
14 Sep 22
Immunoprecise Antibodies LTD. 6-K
8:04am
40-F
EX-99.1
n77a0q1hk r7g2ktfag
29 Jul 22
Annual report (Canada)
9:04am
40-F
EX-99.3
zijr1bo aehrb14ncb
29 Jul 22
Annual report (Canada)
9:04am
6-K
EX-99.1
7efwn1at5q wxx0hcij
16 Mar 22
FY22 Q3 6-K
8:00am
6-K
EX-99.1
5p6 w5uozk
14 Mar 22
Immunoprecise Antibodies LTD. 6-K
9:35am